10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

50 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Research Site, Cheonan, Chungcheongnam-do, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Early Breast Cancer patients
Postmenopausal Status
patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion criteria

Advanced Breast Cancer patients(stage iii, iv)
Patients who are hard to be analysed by limitation of chart record according to investigators discretion
patients who already have been registered in this study

Treatment and study plan

Primary outcomes

The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.

Time frame: 1 visit

Secondary outcomes

To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer

Time frame: 1 Visit
To analyse CHD management patterns according to defined 10-year CHD risk categories

Time frame: 1 Visit
To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk

Time frame: 1 Visit

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Apr 22, 2009
Registry last updated: Jun 29, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed